You are here

linvoseltamab

FDA declines to approve Regeneron's blood cancer therapy

Reuters

Tue, 08/20/24 - 09:59 pm

Multiple Myeloma

Regeneron touts possible 'best-in-class' myeloma bispecific, but adverse events climb to 100%

Fierce Biotech

Thu, 12/7/23 - 11:52 am

clinical trials

Multiple Myeloma

Regeneron’s linvoseltamab shows early and durable response in pre-treated MM

Clinical Trials Arena

Fri, 09/29/23 - 11:38 am

clinical trials

bispecific antibodies